Cargando…

Role of oral teriflunomide in the management of multiple sclerosis

The landscape of the treatment of relapsing–remitting multiple sclerosis is changing fast. Several oral treatments have shown benefit and generate much interest because of the convenience of their administration. Two oral compounds, fingolimod and teriflunomide, have been approved in relapsing–remit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tanasescu, Radu, Evangelou, Nikos, Constantinescu, Cris S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3639219/ https://www.ncbi.nlm.nih.gov/pubmed/23637535 http://dx.doi.org/10.2147/NDT.S31248

Ejemplares similares

An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis
por: Dumitrescu, Laura, et al.
Publicado: (2023)

Granulocyte-Macrophage Colony-Stimulating Factor as a Therapeutic Target in Multiple Sclerosis
por: Aram, Jehan, et al.
Publicado: (2018)

An update of teriflunomide for treatment of multiple sclerosis
por: Oh, Jiwon, et al.
Publicado: (2013)

Teriflunomide and Its Mechanism of Action in Multiple Sclerosis
por: Bar-Or, Amit, et al.
Publicado: (2014)

Review of teriflunomide and its potential in the treatment of multiple sclerosis
por: Warnke, Clemens, et al.
Publicado: (2009)

Localised Grey Matter Atrophy in Multiple Sclerosis and Clinically Isolated Syndrome—A Coordinate-Based Meta-Analysis, Meta-Analysis of Networks, and Meta-Regression of Voxel-Based Morphometry Studies
por: Singh, Sonika, et al.
Publicado: (2020)

Teriflunomide in Patients with Relapsing–Remitting Forms of Multiple Sclerosis
por: Chan, Andrew, et al.
Publicado: (2016)

An Absence of Epstein–Barr Virus Reactivation and Associations with Disease Activity in People with Multiple Sclerosis Undergoing Therapeutic Hookworm Vaccination
por: Maple, Peter A. C., et al.
Publicado: (2020)

Oral teriflunomide in the treatment of relapsing forms of multiple sclerosis: clinical evidence and long-term experience
por: Miller, Aaron E.
Publicado: (2017)

Neuropathy in multiple sclerosis patients treated with teriflunomide
por: Kilic, Ahmet Kasim, et al.
Publicado: (2023)

The association between human endogenous retroviruses and multiple sclerosis: A systematic review and meta-analysis
por: Morandi, Elena, et al.
Publicado: (2017)

Teriflunomide for the treatment of relapsing–remitting multiple sclerosis: patient preference and adherence
por: Bayas, Antonios, et al.
Publicado: (2015)

COVID-19 in teriflunomide-treated patients with multiple sclerosis
por: Maghzi, Amir Hadi, et al.
Publicado: (2020)

Teriflunomide Safety and Efficacy in Advanced Progressive Multiple Sclerosis
por: Moreira Ferreira, Vanessa F., et al.
Publicado: (2020)

Vaccine Response in Patients With Multiple Sclerosis Receiving Teriflunomide
por: Tornatore, Carlo, et al.
Publicado: (2022)

Predictors of long-term disability in multiple sclerosis patients using routine magnetic resonance imaging data: A 15-year retrospective study
por: Altokhis, Amjad, et al.
Publicado: (2023)

Prevalence of a history of prior varicella/herpes zoster infection in multiple sclerosis
por: Manouchehrinia, Ali, et al.
Publicado: (2017)

Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis
por: Laplaud, David-Axel, et al.
Publicado: (2019)

From Leflunomide to Teriflunomide: Drug Development and Immuno-suppressive Oral Drugs in the Treatment of Multiple Sclerosis
por: Aly, Lilian, et al.
Publicado: (2017)

Experimental infection with the hookworm, Necator americanus, is associated with stable gut microbial diversity in human volunteers with relapsing multiple sclerosis
por: Jenkins, Timothy P., et al.
Publicado: (2021)

Natalizumab Treatment of Relapsing Remitting Multiple Sclerosis Has No Long-Term Effects on the Proportion of Circulating Regulatory T Cells
por: Tanasescu, Radu, et al.
Publicado: (2023)

Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis
por: Bar-Or, Amit, et al.
Publicado: (2013)

Safe Childbirth after Taking Teriflunomide in a Woman with Multiple Sclerosis
por: Cho, Bang-Hoon, et al.
Publicado: (2018)

Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis
por: Comi, Giancarlo, et al.
Publicado: (2020)

Teriflunomide treatment is associated with optic nerve recovery in early multiple sclerosis
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

Real-world discontinuation rate of teriflunomide and dimethyl fumarate in multiple sclerosis
por: Norborg, Hilde, et al.
Publicado: (2021)

CSF lymphocytic pleocytosis does not predict a less favourable long-term prognosis in MS
por: Astbury, Lauren, et al.
Publicado: (2022)

Editorial: Preventing multiple sclerosis
por: Dobson, Ruth, et al.
Publicado: (2022)

Increased IL-2 and Reduced TGF-β Upon T-Cell Stimulation are Associated with GM-CSF Upregulation in Multiple Immune Cell Types in Multiple Sclerosis
por: Aram, Jehan, et al.
Publicado: (2020)

A randomized trial of teriflunomide added to glatiramer acetate in relapsing multiple sclerosis
por: Freedman, MS, et al.
Publicado: (2015)

Teriflunomide Treatment of Multiple Sclerosis Selectively Modulates CD8 Memory T Cells
por: Tilly, Gaëlle, et al.
Publicado: (2021)

Teriflunomide in relapsing-remitting multiple sclerosis: outcomes by age and pre-treatment status
por: Kallmann, Boris A., et al.
Publicado: (2021)

Serum Levels of CXCL13 Are Associated With Teriflunomide Response in Patients With Multiple Sclerosis
por: Fissolo, Nicolás, et al.
Publicado: (2022)

Teriflunomide treatment outcomes in multiple sclerosis: A Portuguese real-life experience
por: Nunes, Carla Cecília, et al.
Publicado: (2023)

Natalizumab Treatment for Relapsing Multiple Sclerosis Stabilises Normal-Appearing White Matter Microstructure: A One-Year Prospective Ultra-High-Field Quantitative Imaging Study
por: Tanasescu, Radu, et al.
Publicado: (2023)

Reducing return of disease activity in patients with relapsing multiple sclerosis transitioned from natalizumab to teriflunomide: 12-month interim results of teriflunomide therapy
por: Cohan, Stanley L, et al.
Publicado: (2019)

Real-world effectiveness and safety profile of teriflunomide in the management of multiple sclerosis in the Gulf Cooperation Council countries: An expert consensus narrative review
por: Alroughani, Raed, et al.
Publicado: (2022)

A comparison of phase imaging and quantitative susceptibility mapping in the imaging of multiple sclerosis lesions at ultrahigh field
por: Cronin, Matthew John, et al.
Publicado: (2016)

Coordinate Based Meta-Analysis of Functional Neuroimaging Data; False Discovery Control and Diagnostics
por: Tench, Christopher R., et al.
Publicado: (2013)

Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide
por: Bollo, Luca, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mkaqf9sdhirov5p5j405hi8com